Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases

Ludmila Katherine Martin, Anthony Cucci, Lai Wei, Jeffrey Rose, Marlo Blazer, Carl Schmidt, Hooman Khabiri, Mark Bloomston, Tanios Bekaii-Saab

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Few patients with metastatic colorectal cancer (mCRC) are candidates for resection of their hepatic disease. Yttrium-90 (90Y) radioembolization has promise in the treatment of unresectable mCRC. We conducted a retrospective study to assess the efficacy in patients with refractory mCRC who underwent 90Y radioembolization. Patients with unresectable mCRC with liver metastases treated at The Ohio State University were included in this analysis. Demographic data, carcinoembryonic antigen (CEA) values, observed toxicities, and information on prior therapies were collected. Response was assessed by RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Twenty-four patients (median age, 63 years) were included. Of the patients, 54% had extrahepatic disease; 67% had bilobar involvement. The patients had received a median of 3 prior therapies. No objective responses were observed. Five patients had a CEA response. Median PFS and OS were 3.9 months (95% CI, 2.4-4.8 months) and 8.9 months (95% CI, 4.2-16.7 months), respectively. Patients older than 65 years had improved PFS (4.6 vs. 2.4 months) and OS (14 vs. 5.5 months) vs. younger patients, likely due to receipt of 90Y treatment earlier in their disease course. The presence of extrahepatic disease and the absence of CEA response appeared negatively predictive of efficacy. Toxicities were expected and manageable. 90Y radioembolization is active in select patients with refractory mCRC and with liver metastases, and is safe and well tolerated in the elderly. In patients with extensive extrahepatic disease, 90Y should be used in combination with chemotherapy. CEA may be a predictor of efficacy.

Original languageEnglish (US)
Pages (from-to)195-199
Number of pages5
JournalClinical Colorectal Cancer
Volume11
Issue number3
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Yttrium
Salvage Therapy
Liver Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Carcinoembryonic Antigen
Disease-Free Survival
Survival
Therapeutics
Combination Drug Therapy
Retrospective Studies
Demography

Keywords

  • Colorectal cancer
  • Hepatic
  • Locoregional
  • Radioembolization
  • Y-90

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. / Martin, Ludmila Katherine; Cucci, Anthony; Wei, Lai; Rose, Jeffrey; Blazer, Marlo; Schmidt, Carl; Khabiri, Hooman; Bloomston, Mark; Bekaii-Saab, Tanios.

In: Clinical Colorectal Cancer, Vol. 11, No. 3, 01.01.2012, p. 195-199.

Research output: Contribution to journalArticle

Martin, LK, Cucci, A, Wei, L, Rose, J, Blazer, M, Schmidt, C, Khabiri, H, Bloomston, M & Bekaii-Saab, T 2012, 'Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases', Clinical Colorectal Cancer, vol. 11, no. 3, pp. 195-199. https://doi.org/10.1016/j.clcc.2011.12.002
Martin, Ludmila Katherine ; Cucci, Anthony ; Wei, Lai ; Rose, Jeffrey ; Blazer, Marlo ; Schmidt, Carl ; Khabiri, Hooman ; Bloomston, Mark ; Bekaii-Saab, Tanios. / Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. In: Clinical Colorectal Cancer. 2012 ; Vol. 11, No. 3. pp. 195-199.
@article{b36bd64b752b42ec81ae7ad019974cb0,
title = "Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases",
abstract = "Few patients with metastatic colorectal cancer (mCRC) are candidates for resection of their hepatic disease. Yttrium-90 (90Y) radioembolization has promise in the treatment of unresectable mCRC. We conducted a retrospective study to assess the efficacy in patients with refractory mCRC who underwent 90Y radioembolization. Patients with unresectable mCRC with liver metastases treated at The Ohio State University were included in this analysis. Demographic data, carcinoembryonic antigen (CEA) values, observed toxicities, and information on prior therapies were collected. Response was assessed by RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Twenty-four patients (median age, 63 years) were included. Of the patients, 54{\%} had extrahepatic disease; 67{\%} had bilobar involvement. The patients had received a median of 3 prior therapies. No objective responses were observed. Five patients had a CEA response. Median PFS and OS were 3.9 months (95{\%} CI, 2.4-4.8 months) and 8.9 months (95{\%} CI, 4.2-16.7 months), respectively. Patients older than 65 years had improved PFS (4.6 vs. 2.4 months) and OS (14 vs. 5.5 months) vs. younger patients, likely due to receipt of 90Y treatment earlier in their disease course. The presence of extrahepatic disease and the absence of CEA response appeared negatively predictive of efficacy. Toxicities were expected and manageable. 90Y radioembolization is active in select patients with refractory mCRC and with liver metastases, and is safe and well tolerated in the elderly. In patients with extensive extrahepatic disease, 90Y should be used in combination with chemotherapy. CEA may be a predictor of efficacy.",
keywords = "Colorectal cancer, Hepatic, Locoregional, Radioembolization, Y-90",
author = "Martin, {Ludmila Katherine} and Anthony Cucci and Lai Wei and Jeffrey Rose and Marlo Blazer and Carl Schmidt and Hooman Khabiri and Mark Bloomston and Tanios Bekaii-Saab",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.clcc.2011.12.002",
language = "English (US)",
volume = "11",
pages = "195--199",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases

AU - Martin, Ludmila Katherine

AU - Cucci, Anthony

AU - Wei, Lai

AU - Rose, Jeffrey

AU - Blazer, Marlo

AU - Schmidt, Carl

AU - Khabiri, Hooman

AU - Bloomston, Mark

AU - Bekaii-Saab, Tanios

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Few patients with metastatic colorectal cancer (mCRC) are candidates for resection of their hepatic disease. Yttrium-90 (90Y) radioembolization has promise in the treatment of unresectable mCRC. We conducted a retrospective study to assess the efficacy in patients with refractory mCRC who underwent 90Y radioembolization. Patients with unresectable mCRC with liver metastases treated at The Ohio State University were included in this analysis. Demographic data, carcinoembryonic antigen (CEA) values, observed toxicities, and information on prior therapies were collected. Response was assessed by RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Twenty-four patients (median age, 63 years) were included. Of the patients, 54% had extrahepatic disease; 67% had bilobar involvement. The patients had received a median of 3 prior therapies. No objective responses were observed. Five patients had a CEA response. Median PFS and OS were 3.9 months (95% CI, 2.4-4.8 months) and 8.9 months (95% CI, 4.2-16.7 months), respectively. Patients older than 65 years had improved PFS (4.6 vs. 2.4 months) and OS (14 vs. 5.5 months) vs. younger patients, likely due to receipt of 90Y treatment earlier in their disease course. The presence of extrahepatic disease and the absence of CEA response appeared negatively predictive of efficacy. Toxicities were expected and manageable. 90Y radioembolization is active in select patients with refractory mCRC and with liver metastases, and is safe and well tolerated in the elderly. In patients with extensive extrahepatic disease, 90Y should be used in combination with chemotherapy. CEA may be a predictor of efficacy.

AB - Few patients with metastatic colorectal cancer (mCRC) are candidates for resection of their hepatic disease. Yttrium-90 (90Y) radioembolization has promise in the treatment of unresectable mCRC. We conducted a retrospective study to assess the efficacy in patients with refractory mCRC who underwent 90Y radioembolization. Patients with unresectable mCRC with liver metastases treated at The Ohio State University were included in this analysis. Demographic data, carcinoembryonic antigen (CEA) values, observed toxicities, and information on prior therapies were collected. Response was assessed by RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Twenty-four patients (median age, 63 years) were included. Of the patients, 54% had extrahepatic disease; 67% had bilobar involvement. The patients had received a median of 3 prior therapies. No objective responses were observed. Five patients had a CEA response. Median PFS and OS were 3.9 months (95% CI, 2.4-4.8 months) and 8.9 months (95% CI, 4.2-16.7 months), respectively. Patients older than 65 years had improved PFS (4.6 vs. 2.4 months) and OS (14 vs. 5.5 months) vs. younger patients, likely due to receipt of 90Y treatment earlier in their disease course. The presence of extrahepatic disease and the absence of CEA response appeared negatively predictive of efficacy. Toxicities were expected and manageable. 90Y radioembolization is active in select patients with refractory mCRC and with liver metastases, and is safe and well tolerated in the elderly. In patients with extensive extrahepatic disease, 90Y should be used in combination with chemotherapy. CEA may be a predictor of efficacy.

KW - Colorectal cancer

KW - Hepatic

KW - Locoregional

KW - Radioembolization

KW - Y-90

UR - http://www.scopus.com/inward/record.url?scp=84865448894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865448894&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2011.12.002

DO - 10.1016/j.clcc.2011.12.002

M3 - Article

VL - 11

SP - 195

EP - 199

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 3

ER -